ArticleCancer cell2026
Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence.
Abstract read
In one paragraph
Article in Cancer cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Spatial Omics Technologies in Glioblastoma Research: Principles, Applications, and Best Practices.Genes · 2026Review
- Integrative spatial multi-omics reveals the tumor ecosystem: From mechanistic insights to therapeutic strategies.iScience · 2026Review
- The glycobiology of prostate cancer: an update.Oncogene · 2026Review
- Engineering an AIEgen-based platform integrating CRISPR/Cas9 to remodel the tumor microenvironment and reinforce photo-immunotherapy against glioblastom.Signal transduction and targeted therapy · 2026Article
- Leveraging single-cell and spatial omics for brain tumour insights to improve therapeutic strategies.Molecular brain · 2026Review
- Tunable Technologies for the Glioma Tumor Microenvironment: A Comprehensive Review on Bench-to-Bedside Neurosurgical Advances.Brain sciences · 2026Review
- Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Glioblastoma Stem Cells as Targets for Emerging Precision Immunotherapies and Molecular Treatments.Cells · 2026Review
- Spatial omics and AI for clinically actionable cancer biomarkers.PLoS medicine · 2026Article
- PHF23-Related Prognostic Signature Modulates Immune Microenvironment and Promotes Tumor Malignancy in Glioma.International journal of molecular sciences · 2026Article
- Dissecting the aberrant vasculature of glioblastoma: mechanisms and therapeutic targets.Cancer metastasis reviews · 2026Review
- The automated computational workflow QUICHE reveals structural definitions of antitumor responses in triple-negative breast cancer.Nature cancer · 2026Article
- Nested ecosystems theory for conceptualizing brain tumors.Disease models & mechanisms · 2026Review
- Harnessing Cuproptosis resistance to advance cancer therapeutics.Apoptosis : an international journal on programmed cell death · 2026Review
- Immunometabolic control of macrophage plasticity in wound healing: mechanistic insights and therapeutic opportunities.Frontiers in immunology · 2026Review
- Streamlining Multiplexed Tissue Image Analysis with PIPΣX: An Integrated Automated Pipeline for Image Processing and EXploration for Diverse Tissue Types.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
- Update of
Authors and funding
40 authors.
Hadeesha PiyadasaDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Benjamin OberltonDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Immunology Program, Stanford University School of Medicine, Stanford, CA, USA.
Mikaela RibiDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Department of Chemistry and Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
Ke LeowDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA.
Jolene S RanekDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Inna AverbukhDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Meelad AmouzgarDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Immunology Program, Stanford University School of Medicine, Stanford, CA, USA.
Candace C LiuDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Immunology Program, Stanford University School of Medicine, Stanford, CA, USA.
Davide G FranchinaDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Noah F GreenwaldDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA.
Erin F McCaffreyDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Rashmi KumarDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Selena FerrianDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Albert G TsaiDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Ferda FilizDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Christine Camacho FullawayDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Marc BosseDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Sricharan Reddy VarraDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Alex KongDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Cameron SowersDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Melanie Hayden GephartDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
Pablo Nuñez-PerezDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
EnJun YangParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Mike TraversParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Michael J SchachterParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Samantha LiangParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Maria R SantiChildren's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Samantha BucktroutParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Pier Federico GherardiniParker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Biology, University of Rome "Tor Vergata", Rome, Italy.
John ConnollyParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Kristina ColeChildren's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Michael E BarishParker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
Christine E BrownDepartments of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
Derek A OldridgeParker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Center for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Richard R DrakeDepartment of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Joanna J PhillipsDepartment of Pathology, University of California, San Francisco, San Francisco, CA, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Hideho OkadaParker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Robert PrinsParker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Neurosurgery, UCLA, Los Angeles, CA, USA.
Sean C BendallDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Immunology Program, Stanford University School of Medicine, Stanford, CA, USA; Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Electronic address: bendall@stanford.edu.
Michael AngeloDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Immunology Program, Stanford University School of Medicine, Stanford, CA, USA; Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Electronic address: mangelo0@stanford.edu.
Funding
Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4MStanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PDP30AG066515 · NIA · STANFORD UNIVERSITY · PI Lisa Goldman Rosas · 2020 to 2026
$29.0MMOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2MStanford Cancer Immune Monitoring and Analysis Center (CIMAC)U24CA224309 · NCI · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Holden T. Maecker · 2017 to 2026
$19.9MPreclinical development of breakthrough immunotherapy for brain tumorsR35NS105068 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2018 to 2025
$6.0MThe Bone Marrow Multi-modal Imaging CoreU54HL165445 · NHLBI · STANFORD UNIVERSITY · PI ANGELO, ROBERT MICHAEL, BENDALL, SEAN CURTIS · 2022 to 2025
$5.9MMIRIAD - Multiplexed Imaging of Resilience In Alzheimers DiseaseR01AG057915 · NIA · STANFORD UNIVERSITY · PI ANGELO, ROBERT MICHAEL, BENDALL, SEAN CURTIS · 2017 to 2021
$4.5MThe Phenotypic Landscape of Cognitive Decline as Revealed by Next-Generation Multiplexed Ion Beam ImagingR01AG056287 · NIA · STANFORD UNIVERSITY · PI ANGELO, ROBERT MICHAEL, BENDALL, SEAN CURTIS · 2017 to 2021
$2.6MUncoupling Age- Versus Cognitive-Related Cellular Senescence in Alzheimer's DiseaseR01AG068279 · NIA · STANFORD UNIVERSITY · PI BENDALL, SEAN CURTIS · 2020 to 2024
$1.9MRegulating the glioma immune microenvironmentR01NS131474 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joanna Phillips · 2024 to 2026
$1.8MNCI NIH HHS P50 CA097257NCI NIH HHS P50 CA211015NCI NIH HHS U24 CA224309NHLBI NIH HHS U54 HL165445NIAID NIH HHS T32 AI007290NIA NIH HHS P30 AG066515NIA NIH HHS R01 AG056287NIA NIH HHS R01 AG057915NIA NIH HHS R01 AG068279NINDS NIH HHS R01 NS131474NINDS NIH HHS R35 NS105068
Abstract
Gliomas are among the most lethal cancers, with limited treatment options. To uncover hallmarks of therapeutic escape and tumor microenvironment (TME) landscape, we applied spatial proteomics, transcriptomics, and glycomics to 670 lesions from 310 adult and pediatric patients. Single-cell analysis shows high B7H3+ tumor cell prevalence in glioblastoma (GBM) and pleomorphic xanthoastrocytoma, while most gliomas, including pediatric cases, express targetable tumor antigens in less than 50% of tumor cells, potentially explaining trial failures. Paired samples of isocitrate dehydrogenase (IDH)-mutant gliomas reveal recurrence driven by tumor-immune spatial reorganization, shifting from T cell and vasculature-associated myeloid cell-enriched niches to microglia and CD206
Indexed as
Brain NeoplasmsGliomaNeoplasm Recurrence, LocalAdultBiomarkers, TumorChildFemaleGene Expression ProfilingGlioblastomaGlycomicsHumansIsocitrate DehydrogenaseMaleMiddle AgedMultiomicsMutationBiomarkers, TumorIsocitrate Dehydrogenasediffuse midline gliomaGBMgliomaimmune regulationimmunotherapysingle-cell profilingspatial multi-omicsspatial N-glycomeTMEtumor antigens
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.